PubRank

Carlos García-Echeverría

Author PubWeight™ 72.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008 14.47
2 Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008 10.35
3 Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 2009 4.02
4 Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010 3.53
5 Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 2010 3.40
6 Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004 3.25
7 The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A 2008 3.13
8 Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010 2.86
9 Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2011 2.73
10 Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem 2003 2.23
11 Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 2008 2.15
12 Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005 2.09
13 Exploring amyloid formation by a de novo design. Proc Natl Acad Sci U S A 2004 1.55
14 NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 2010 1.52
15 The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 2005 1.38
16 Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorg Med Chem Lett 2007 1.38
17 PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr Opin Cell Biol 2009 1.34
18 Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 2005 1.30
19 Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007 1.25
20 PI3K inhibitors for cancer treatment: where do we stand? Biochem Soc Trans 2009 1.18
21 High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy. Eur J Cancer 2009 1.00
22 The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol Cancer Ther 2004 0.96
23 Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells. FEBS Lett 2002 0.87
24 Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design. J Med Chem 2004 0.85
25 The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br J Haematol 2008 0.85
26 Blocking the PI3K/PKB pathway in tumor cells. Curr Med Chem Anticancer Agents 2005 0.80
27 Targeting protein kinases in cancer therapy. Curr Opin Drug Discov Devel 2002 0.80
28 Structure-based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome. Bioorg Med Chem Lett 2002 0.80
29 Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinoma. Mol Cancer Res 2012 0.79
30 Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells. Int J Pept Res Ther 2006 0.77
31 Novel beta-lactam derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome. Bioorg Med Chem Lett 2006 0.76